Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Core Insights - Spyre Therapeutics is on track to deliver six proof-of-concept readouts in 2026 from its SKYLINE and SKYWAY Phase 2 trials, with initial results from the SKYLINE trial in ulcerative colitis expected in Q2 2026 and results from the SKYWAY trial in rheumatic diseases anticipated in Q4 2026 [1][4][5] Financial Overview - As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $757 million, providing a financial runway into the second half of 2028 [1][13] - The company raised $316.2 million in gross proceeds from a public offering of common stock in October 2025 [13] - Research and Development (R&D) expenses for Q4 2025 were $44.6 million, a decrease from $50.5 million in Q4 2024, primarily due to lower early-stage R&D activities [14] - General and Administrative (G&A) expenses increased to $12.5 million in Q4 2025 from $10.8 million in Q4 2024, driven by higher headcount [14] Development Pipeline - The company is developing long-acting antibodies targeting α4β7, TL1A, and IL-23 to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases [3][17] - The SKYLINE Phase 2 trial includes an open-label assessment of safety and preliminary efficacy for investigational monotherapies in patients with moderately to severely active ulcerative colitis, with data readouts expected to begin in 2026 [4][10] - The SKYWAY Phase 2 trial is evaluating the anti-TL1A antibody in three rheumatic diseases, with proof-of-concept data expected in Q4 2026 [5][10] Clinical Trials - The investigational therapies in the SKYLINE and SKYWAY trials include SPY001, SPY002, SPY072, and SPY003, all designed for infrequent subcutaneous maintenance dosing [6][7][8] - SPY001 targets α4β7, while SPY002 and SPY072 are anti-TL1A antibodies, and SPY003 targets the p19 subunit of IL-23 [6][7][8] - The company plans to investigate rational combinations of its proprietary antibodies in clinical trials to enhance efficacy in IBD [9][19] Market Context - IBD affects approximately 2.4 million individuals in the U.S., while rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis collectively impact over three million individuals [3]